www.TheFinancialMarketingGroup.com
Followers | 59 |
Posts | 2,197 |
Boards Moderated | 4 |
Alias Born | 04/28/2019 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$WING The market must be near the top WINGSTOP has 121 P/E
We will keep this quite simple IT SELLS CHICKEN AND HAS A 121 P/E RATIO, its average analysts price target is $78, this just does not make sense regardless of growth and lower staffing costs, it is still chicken not some sort of TECH unicorn. Analysts recently questioned NYSE:MCD for having A 27 P/E. We will be waiting for this to run out of steam and when it does watch out below, it will run to $80 very fast and don't rule out $50 for a bottom.
$WING The market must be near the top WINGSTOP has 121 P/E
We will keep this quite simple IT SELLS CHICKEN AND HAS A 121 P/E RATIO, its average analysts price target is $78, this just does not make sense regardless of growth and lower staffing costs, it is still chicken not some sort of TECH unicorn. Analysts recently questioned NYSE:MCD for having A 27 P/E. We will be waiting for this to run out of steam and when it does watch out below, it will run to $80 very fast and don't rule out $50 for a bottom.
$MRK Merck & CO Inc. still in 19 year recovery cycle
On the daily chart of NYSE:MRK it seems that a nice breakout rally is setting up, with $84 as a good point to evaluate your position. The chart accompanying this post is merely a look at the nature of declines that a stock can suffer, to get back to the 2000 price level may take a possible 21 years, that is a long to hold and pray. It teaches us the lesson that stocks can keep going down, so accept you lose quickly and don't wait 20 years for it to claw its way back. Every company that we invest in is just one mistake or headline away from the fate of falling like a stone and the only ones left holding on are those who just couldn't accept the loss in the hope it will be different next week.
"even the mighty can fall"
AVERAGE ANALYSTS PRICE TARGET $88
AVERAGE ANALYSTS RECOMMENDATION BUY
P/E RATIO 26
COMPANY PROFILE
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines , vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical , Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
$MRK Merck & CO Inc. still in 19 year recovery cycle
On the daily chart of NYSE:MRK it seems that a nice breakout rally is setting up, with $84 as a good point to evaluate your position. The chart accompanying this post is merely a look at the nature of declines that a stock can suffer, to get back to the 2000 price level may take a possible 21 years, that is a long to hold and pray. It teaches us the lesson that stocks can keep going down, so accept you lose quickly and don't wait 20 years for it to claw its way back. Every company that we invest in is just one mistake or headline away from the fate of falling like a stone and the only ones left holding on are those who just couldn't accept the loss in the hope it will be different next week.
"even the mighty can fall"
AVERAGE ANALYSTS PRICE TARGET $88
AVERAGE ANALYSTS RECOMMENDATION BUY
P/E RATIO 26
COMPANY PROFILE
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines , vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical , Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
$MPW A Medical Reit with 6.7 P/E and 5.6% dividend Yield
One thing we can be certain of, is that people will get sick and NYSE:MPW is to the forefront of benefiting from that fact. The company is a REIT that owns and continues to acquire healthcare facilities of all types.Their portfolio includes properties in the USA, Germany, Australia and Switzerland, which are all very profitable investments. Currently the stock is in a nice trajectory within a well defined support trendline and resistance trendline (red), while also having support from the 50/100/200 MA', indicators are also bullish . At a time of great uncertainty and volatility a REIT such as this is a great stock to own within your portfolio offering a good dividend yield and the security of a very reasonable PE ratio.
We expect the stock to get upgraded in the days and weeks to come as it has already reached its average analysts target, this could initiate the imminent breakout. Set alerts for above $19 on good volume .
AVERAGE ANALYSTS PRICE TARGET $19
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/E RATION 6.7
COMPANY PROFILE
Medical Properties Trust, Inc. is a self-advised real estate investment trust, which engages in investing and owning net-leased healthcare facilities across the United States of America and selective foreign countries. It focuses on funding hospitals and other facilities where patients must be admitted by doctors. The company was founded by Edward K. Aldag Jr., R. Steven Hamner, Emmett E McLean, and William G. McKenzie on August 27, 2003 and is headquartered in Birmingham, AL.
$MPW A Medical Reit with 6.7 P/E and 5.6% dividend Yield
One thing we can be certain of, is that people will get sick and NYSE:MPW is to the forefront of benefiting from that fact. The company is a REIT that owns and continues to acquire healthcare facilities of all types.Their portfolio includes properties in the USA, Germany, Australia and Switzerland, which are all very profitable investments. Currently the stock is in a nice trajectory within a well defined support trendline and resistance trendline (red), while also having support from the 50/100/200 MA', indicators are also bullish . At a time of great uncertainty and volatility a REIT such as this is a great stock to own within your portfolio offering a good dividend yield and the security of a very reasonable PE ratio.
We expect the stock to get upgraded in the days and weeks to come as it has already reached its average analysts target, this could initiate the imminent breakout. Set alerts for above $19 on good volume .
AVERAGE ANALYSTS PRICE TARGET $19
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/E RATION 6.7
COMPANY PROFILE
Medical Properties Trust, Inc. is a self-advised real estate investment trust, which engages in investing and owning net-leased healthcare facilities across the United States of America and selective foreign countries. It focuses on funding hospitals and other facilities where patients must be admitted by doctors. The company was founded by Edward K. Aldag Jr., R. Steven Hamner, Emmett E McLean, and William G. McKenzie on August 27, 2003 and is headquartered in Birmingham, AL.
$TRP Reversal trade looks appealing, selling is overdone.
Post earnings the stock of NYSE:TPR spiked higher but it was short lived, losing 23% from that high, China is the obvious problem for Tapestry as tariffs are going to take a large bite out of earnings . As the rhetoric became more and more negative between the USA and China retailers have witnessed drastic declines in their share price. Since the earnings report the company has announced the arrival of a new COO formerly of VFC and it is notable that one of the company directors bought a sizeable chunk of stock in May also. Indicators on the chart are pointing to a recovery and have taken a much more bullish setup.
AVERAGE ANALYSTS PRICE TARGET $43.37
AVERAGE ANALYSTS RECOMMENDATION overweight
P/E RATIO 12.48
COMPANY PROFILE
Tapestry, Inc. engages in the provision of luxury accessories and lifestyle brands. It operates through the following segments:Coach, Kate Spade, and Stuart Weitzman. The Coach segment consists global sales of coach brand products to customers through coach operated stores, including the internet and concession shop-in-shops, and sales to wholesale customers, and through independent third party distributors. The Kate Spade segment focuses in the kate spade new york brand products to customers through Kate Spade operated stores. The Stuart Weitzman segment comprises Stuart Weitzman brand products primarily through Stuart Weitzman operated stores. The company was founded by Dawn Hughes in 1941 and is headquartered in New York , NY.
$TRP Reversal trade looks appealing, selling is overdone.
Post earnings the stock of NYSE:TPR spiked higher but it was short lived, losing 23% from that high, China is the obvious problem for Tapestry as tariffs are going to take a large bite out of earnings . As the rhetoric became more and more negative between the USA and China retailers have witnessed drastic declines in their share price. Since the earnings report the company has announced the arrival of a new COO formerly of VFC and it is notable that one of the company directors bought a sizeable chunk of stock in May also. Indicators on the chart are pointing to a recovery and have taken a much more bullish setup.
AVERAGE ANALYSTS PRICE TARGET $43.37
AVERAGE ANALYSTS RECOMMENDATION overweight
P/E RATIO 12.48
COMPANY PROFILE
Tapestry, Inc. engages in the provision of luxury accessories and lifestyle brands. It operates through the following segments:Coach, Kate Spade, and Stuart Weitzman. The Coach segment consists global sales of coach brand products to customers through coach operated stores, including the internet and concession shop-in-shops, and sales to wholesale customers, and through independent third party distributors. The Kate Spade segment focuses in the kate spade new york brand products to customers through Kate Spade operated stores. The Stuart Weitzman segment comprises Stuart Weitzman brand products primarily through Stuart Weitzman operated stores. The company was founded by Dawn Hughes in 1941 and is headquartered in New York , NY.
$DNKN DUNKIN IS BREAKING OUT, BULLISH CHART
The stock of NASDAQ:DNKN has gained great momentum in recent months, continuing a six quarter winning streak on earnings beats. The company continues to grow at pace while introducing
new menu items , loyalty programs and digitization. The stock does have a considerably high valuation with a 28.36 P/E ratio , which makes it interesting to see how analysts will rerate the stock now it is above the average target price. Headwinds are ahead for the brand as the labour market is becoming very tight and competition fierce, this is however slightly offset by the reduction in coffee costs. The chart is extremely bullish with a horizontal breakout and a inverse H&S playing out on strong volume , while indicators are all bullish . There may be a better opportunity on a pullback to enter the stock, our upside target is $85.
$DNKN DUNKIN IS BREAKING OUT, BULLISH CHART
The stock of NASDAQ:DNKN has gained great momentum in recent months, continuing a six quarter winning streak on earnings beats. The company continues to grow at pace while introducing
new menu items , loyalty programs and digitization. The stock does have a considerably high valuation with a 28.36 P/E ratio , which makes it interesting to see how analysts will rerate the stock now it is above the average target price. Headwinds are ahead for the brand as the labour market is becoming very tight and competition fierce, this is however slightly offset by the reduction in coffee costs. The chart is extremely bullish with a horizontal breakout and a inverse H&S playing out on strong volume , while indicators are all bullish . There may be a better opportunity on a pullback to enter the stock, our upside target is $85.
$AXP MUCH MORE UPSIDE POTENTIAL IN AMERICAN EXPRESS
Due to the strong move in NYSE:AXP in 2019 it has now reached its analysts average price target, this makes upgrades very possible in the days to follow. From a technical view the chart is perfect, with a strong uptrend and a major breakout completed, indicators are all bullish and buy volume is dominant. This stock is a ideal inclusion for any portfolio and long term investment, as a cashless society becomes more and more likely.
$AXP MUCH MORE UPSIDE POTENTIAL IN AMERICAN EXPRESS
Due to the strong move in NYSE:AXP in 2019 it has now reached its analysts average price target, this makes upgrades very possible in the days to follow. From a technical view the chart is perfect, with a strong uptrend and a major breakout completed, indicators are all bullish and buy volume is dominant. This stock is a ideal inclusion for any portfolio and long term investment, as a cashless society becomes more and more likely.
$THOR So bad it may be good, Reversal trade into earnings
From a fundamental perspective there is not a great deal of reasons to be looking to long the stock of NYSE:THO , but it looks compelling from a technical perspective. The Momentum indicator is seen as a leading indicator and in this case it is bullish as is the RSI and Stoch . This stock has been so beaten down with the entire sector, that any positive news could result in a massive jump post earnings , while there is security from tried and tested support below. This is a risky trade but could be very rewarding.
AVERAGE ANALYSTS PRICE TARGET $76
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
$THOR So bad it may be good, Reversal trade into earnings
From a fundamental perspective there is not a great deal of reasons to be looking to long the stock of NYSE:THO , but it looks compelling from a technical perspective. The Momentum indicator is seen as a leading indicator and in this case it is bullish as is the RSI and Stoch . This stock has been so beaten down with the entire sector, that any positive news could result in a massive jump post earnings , while there is security from tried and tested support below. This is a risky trade but could be very rewarding.
AVERAGE ANALYSTS PRICE TARGET $76
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
$btc They bulls are fighting back but $8200 is a big barrier.
BTC has made a great recovery from the intense selling this week having found strong support in the golden pocket. The price is currently sitting below a strong cluster of resistances, which will be extremely difficult to get through. Recapturing the top side of the middle bollinger band would be extremely bullish , but it sits right on the $8200 level which has been strong resistance in the past. The close tonight could be very volatile as the bears may try to take dominance once again. Be vigilant and it looks like the $7400 level is a area to have stop losses set.
$btc They bulls are fighting back but $8200 is a big barrier.
BTC has made a great recovery from the intense selling this week having found strong support in the golden pocket. The price is currently sitting below a strong cluster of resistances, which will be extremely difficult to get through. Recapturing the top side of the middle bollinger band would be extremely bullish , but it sits right on the $8200 level which has been strong resistance in the past. The close tonight could be very volatile as the bears may try to take dominance once again. Be vigilant and it looks like the $7400 level is a area to have stop losses set.
$LJPC KEEP ON WATCH-LIST FOR MONSTER BREAKOUT
OWAN AND CO RECENTLY ISSUED A BUY RATING AND A $25 PRICE TARGET ON NASDAQ:LJPC RESULTING IN A SPIKE IN PRICE AND VOLUME , WE EXPECT CONTINUATION IN THE DAYS AND WEEKS TO COME FOR SOME GREAT GAINS.
AVERAGE ANALYSTS PRICE TARGET $19.50
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
$LJPC KEEP ON WATCH-LIST FOR MONSTER BREAKOUT
OWAN AND CO RECENTLY ISSUED A BUY RATING AND A $25 PRICE TARGET ON NASDAQ:LJPC RESULTING IN A SPIKE IN PRICE AND VOLUME , WE EXPECT CONTINUATION IN THE DAYS AND WEEKS TO COME FOR SOME GREAT GAINS.
AVERAGE ANALYSTS PRICE TARGET $19.50
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
$LJPC KEEP ON WATCH-LIST FOR MONSTER BREAKOUT
OWAN AND CO RECENTLY ISSUED A BUY RATING AND A $25 PRICE TARGET ON NASDAQ:LJPC RESULTING IN A SPIKE IN PRICE AND VOLUME , WE EXPECT CONTINUATION IN THE DAYS AND WEEKS TO COME FOR SOME GREAT GAINS.
AVERAGE ANALYSTS PRICE TARGET $19.50
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
$HOTH is our low-float Nasdaq listed biotech Breakout alert $10
HOTH (Hoth Therapeutics, Inc.)
Float: 3.86M
Alert Price: $6.57
Target Price: $10.00
Chart Analysis
Investor Presentation
Website | Recent News
========================
Members,
We hope you enjoyed the easy double-digit gains that today's trade idea delivered.
You'll be happy to know that we have already identified an even more exciting trade idea for you.
Please turn your immediate attention to HOTH (Hoth Therapeutics, Inc.)
HOTH is the perfect candidate for a monster move tomorrow.
The Company:
Has a tight float of 3.86M
Operates in the highly volatile biotech sector. (These Stocks Tend to Move Big On News)
Is listed on the Nasdaq Exchange (High Liquidity)
Suffered a sharp pullback today (Perfect "Buy the Dip" Opportunity")
Has a $10 Price Target (+52% Upside)
HOTH has been on our radar for quite some time now. After IPO'ing at $5.50, HOTH went on a tear, hitting a 52-week high of $13.88.
HOTH's recent pullback has created the ultimate buy the dip opportunity for traders.
We all know how explosive these small-cap biotech stocks can be...
Any type of market friendly news could trigger a huge move in share price.
Today we watched RWLK jump over +200% on positive FDA news.
With HOTH's tiny 3.2M float, any type of market friendly news could send shares soaring.
HOTH also has several bullish catalysts on the horizon that have us confident that its $10 price-target is well within reach.
Atopic Dermatitis is a large and growing market
Affects more than 32 million patients in the US
10 20% of all pediatric patients suffer from Atopic Dermatitis
Need for new, differentiated therapies
HOTH's BioLexa Platform offers a non corticosteroid approach to inhibit the formation of biofilms, which increases effectiveness of BioLexa in clearing current symptoms and preventing future flare ups
Phase 2 study is currently being designed by renowned doctors and scientists and on track to start enrollment in Australia by end of 2019
Study will test efficacy, safety, and ease of use
On target to complete Phase 2 clinical trial by end of Q1 2020
As you can see, HOTH is operating in an in-demand market and has several promising products in its pipeline.
Can you imagine how high HOTH shares could go if it were to receive FDA approval?
Based on our research, HOTH appears to be well on its way to becoming our next bio-tech alert to breakout for monster gains.
About HOTH Therapeutics
Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform.
Hoth owns the exclusive rights to develop the BioLexa Platform for all indications in humans. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur.
They intend to explore the use of the BioLexa™ Platform for the treatment of atopic dermatitis, or eczema.
They also intend to explore the use of the BioLexa Platform™ in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures. They believe that the BioLexa Platform™s ability to fight bacterial growth will enable the innate immune system to focus on optimal healing rather than fighting post-procedure infection.
Finally, they intend to explore the use of the BioLexa Platform™ in connection with diabetic foot ulcers. We believe that the BioLexa Platform™s ability to fight bacterial growth will help initiate and/or improve chronic diabetic wound healing as well as accelerate the healing of diabetic wounds with S. aureus.
Genetic Marker License
Hoth has also licensed exclusive rights to certain patented technology from the University of Cincinnati for use in determining the risk that a patient will develop allergies to peanuts, milk and other foods as well as predict propensity for eczema. Hoth’s overall goal is to develop and make ready for commercialization a family of genetic screening tests based on the licensed technology.
Company Highlights:
Unique small cap specialty pharma investment opportunity with multiple shots on goal and capital business model.
Multi-billion market opportunity with large unmet need for both the Company’s primary and secondary asset.
Proprietary platform technology which combines two existing approved drugs enabling reliance on existing safety data for those drugs.
Proprietary BioLexa platform technology which combines two existing approved drugs enabling reliance on existing safety data.
VNLG 152 strong pre-clinical data in acne and psoriasis.
Strong IP Portfolio, including licenses to patents and trademarks.
Signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin.
Experienced management team, board of directors and scientific advisors with proven drug development experience.
Recent Milestones
Entered into licensing agreement with the University of Maryland and Isoprene Pharmaceuticals. (March 2019)
Began pilot study in chronic diabetic ulcers at Mass General Vaccine and Immunotherapy Center (March 2019)
Announced Closing of Initial Public Offering.
Latest News
Hoth and Zylö to use new topical application of an endocannabinoid, anandamide (AEA), in nanoparticles
NEW YORK , May 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that the company has signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin.
Zylö, dedicated to bringing innovative technologies to multiple facets of medicine, has an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented xerogel-derived nanoparticles, called Z-pods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. For more information, please visit; http://www.zylotherapeutics.com/
Scientists at Einstein College of Medicine recently demonstrated that topical administration with AEA-loaded nanoparticles significantly prevents the development of CLE in an established animal model of lupus. This work reinforces and highlights the utility of targeting the endocannabinoid system for autoimmune rheumatic diseases.
The work at Einstein supports the thesis that AEA loaded into Z-pods™ improves drug skin penetration, reduces the expected inflammatory cytokine secretion by keratinocytes when exposed to ultraviolet radiation, prevents the development of CLE skin lesions, improves skin histopathology, prevents inflammation and structural damage on histology and reduces macrophages and C3 accumulation.
According to estimates by the Lupus Foundation of America (LFA), 1.5 Million Americans currently suffer from lupus, with 16,000 new cases reported annually. Tragically, lupus strikes mostly women of child-bearing age. Worldwide, the LFA estimates that at least five million people may have some form of the disease. Of the people diagnosed, approximately two-thirds will develop CLE. The annual average cost to provide medical treatment for a person with lupus: $6,000 to $10,000, with some treatment costing several thousand dollars a month.
"Management is extremely pleased to partner with Zylö Therapeutics, enhancing our portfolio of unique treatments for patients suffering from various dermatological related ailments," stated, Mr. Robb Knie, CEO of Hoth Therapeutics. "Zylö's initial work shows significant promise in combating Cutaneous Lupus Erythematosus, and we look forward to working with them in order to bring this treatment to market."
"We are thrilled to partner with Hoth, a company that is committed to innovative solutions and partnerships to develop treatments for diseases with a high unmet clinical need, such as lupus," said Scott Pancoast, CEO of Zylö. "As we work with the Hoth team to advance AEA-loaded Z-pods through the next stages of development, we expect to further demonstrate the important role that our patented Z-pod delivery system plays in improving treatment outcomes."
The term sheet is non-binding and neither party thereto shall have any obligation to consummate a transaction of any kind until such time as the parties have entered into a mutually agreeable definitive agreement. There can be no assurance that any such definitive agreement will be entered into or that the transaction will be completed on the terms set forth in the term sheet, or at all.
Market Outlook:
Atopic dermatitis market predicted to grow $7.2B in 2017 to $24B by end of 2027.
It affects more than 32 million patients in the US.
Diabetic Foot Ulcers affect approximately 9.1-26.1M people worldwide, about 19 34% of people with diabetes are likely to be affected.
Nearly 7.5 million people are affected by psoriasis in the US alone and represent about 2% of the population with approximately 100,000 new cases reported each year.*
60 million people suffering from all grades of acne in the US, 20% of which is severe enough to result in facial scarring.
Technical Analysis
As we stated above, with HOTH's tiny 3.2M float, any type of market friendly news could send its shares soaring.
HOTH suffered a sharp pullback today creating the perfect "Buy the Dip" opportunity.
HOTH has plenty of room to the upside, a move back to its 52-week high of $13.88 would net traders over +100% in profit from today's alert price.
We've done our very own chart analysis and see the potential for a move to $13.82.
HOTH has shown very little resistance once it breaks $8.80.
We see a strong uptrend, and an impulse to move higher.
This is a potential triple-digit gain opportunity
The Bottom-Line
We love these low-float bio-tech alerts.
They have the tendency to breakout faster and bigger than any other sector.
HOTH has the potential to be the next RWLK , and could lead the NASDAQ in gains tomorrow.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated twenty thousand dollars by Source 4 Communications LLC to conduct a two-day investor relations advertising and marketing campaign for HOTH. . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
$HOTH is our low-float Nasdaq listed biotech Breakout alert $10
HOTH (Hoth Therapeutics, Inc.)
Float: 3.86M
Alert Price: $6.57
Target Price: $10.00
Chart Analysis
Investor Presentation
Website | Recent News
========================
Members,
We hope you enjoyed the easy double-digit gains that today's trade idea delivered.
You'll be happy to know that we have already identified an even more exciting trade idea for you.
Please turn your immediate attention to HOTH (Hoth Therapeutics, Inc.)
HOTH is the perfect candidate for a monster move tomorrow.
The Company:
Has a tight float of 3.86M
Operates in the highly volatile biotech sector. (These Stocks Tend to Move Big On News)
Is listed on the Nasdaq Exchange (High Liquidity)
Suffered a sharp pullback today (Perfect "Buy the Dip" Opportunity")
Has a $10 Price Target (+52% Upside)
HOTH has been on our radar for quite some time now. After IPO'ing at $5.50, HOTH went on a tear, hitting a 52-week high of $13.88.
HOTH's recent pullback has created the ultimate buy the dip opportunity for traders.
We all know how explosive these small-cap biotech stocks can be...
Any type of market friendly news could trigger a huge move in share price.
Today we watched RWLK jump over +200% on positive FDA news.
With HOTH's tiny 3.2M float, any type of market friendly news could send shares soaring.
HOTH also has several bullish catalysts on the horizon that have us confident that its $10 price-target is well within reach.
Atopic Dermatitis is a large and growing market
Affects more than 32 million patients in the US
10 20% of all pediatric patients suffer from Atopic Dermatitis
Need for new, differentiated therapies
HOTH's BioLexa Platform offers a non corticosteroid approach to inhibit the formation of biofilms, which increases effectiveness of BioLexa in clearing current symptoms and preventing future flare ups
Phase 2 study is currently being designed by renowned doctors and scientists and on track to start enrollment in Australia by end of 2019
Study will test efficacy, safety, and ease of use
On target to complete Phase 2 clinical trial by end of Q1 2020
As you can see, HOTH is operating in an in-demand market and has several promising products in its pipeline.
Can you imagine how high HOTH shares could go if it were to receive FDA approval?
Based on our research, HOTH appears to be well on its way to becoming our next bio-tech alert to breakout for monster gains.
About HOTH Therapeutics
Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform.
Hoth owns the exclusive rights to develop the BioLexa Platform for all indications in humans. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur.
They intend to explore the use of the BioLexa™ Platform for the treatment of atopic dermatitis, or eczema.
They also intend to explore the use of the BioLexa Platform™ in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures. They believe that the BioLexa Platform™s ability to fight bacterial growth will enable the innate immune system to focus on optimal healing rather than fighting post-procedure infection.
Finally, they intend to explore the use of the BioLexa Platform™ in connection with diabetic foot ulcers. We believe that the BioLexa Platform™s ability to fight bacterial growth will help initiate and/or improve chronic diabetic wound healing as well as accelerate the healing of diabetic wounds with S. aureus.
Genetic Marker License
Hoth has also licensed exclusive rights to certain patented technology from the University of Cincinnati for use in determining the risk that a patient will develop allergies to peanuts, milk and other foods as well as predict propensity for eczema. Hoth’s overall goal is to develop and make ready for commercialization a family of genetic screening tests based on the licensed technology.
Company Highlights:
Unique small cap specialty pharma investment opportunity with multiple shots on goal and capital business model.
Multi-billion market opportunity with large unmet need for both the Company’s primary and secondary asset.
Proprietary platform technology which combines two existing approved drugs enabling reliance on existing safety data for those drugs.
Proprietary BioLexa platform technology which combines two existing approved drugs enabling reliance on existing safety data.
VNLG 152 strong pre-clinical data in acne and psoriasis.
Strong IP Portfolio, including licenses to patents and trademarks.
Signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin.
Experienced management team, board of directors and scientific advisors with proven drug development experience.
Recent Milestones
Entered into licensing agreement with the University of Maryland and Isoprene Pharmaceuticals. (March 2019)
Began pilot study in chronic diabetic ulcers at Mass General Vaccine and Immunotherapy Center (March 2019)
Announced Closing of Initial Public Offering.
Latest News
Hoth and Zylö to use new topical application of an endocannabinoid, anandamide (AEA), in nanoparticles
NEW YORK , May 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that the company has signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin.
Zylö, dedicated to bringing innovative technologies to multiple facets of medicine, has an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented xerogel-derived nanoparticles, called Z-pods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. For more information, please visit; http://www.zylotherapeutics.com/
Scientists at Einstein College of Medicine recently demonstrated that topical administration with AEA-loaded nanoparticles significantly prevents the development of CLE in an established animal model of lupus. This work reinforces and highlights the utility of targeting the endocannabinoid system for autoimmune rheumatic diseases.
The work at Einstein supports the thesis that AEA loaded into Z-pods™ improves drug skin penetration, reduces the expected inflammatory cytokine secretion by keratinocytes when exposed to ultraviolet radiation, prevents the development of CLE skin lesions, improves skin histopathology, prevents inflammation and structural damage on histology and reduces macrophages and C3 accumulation.
According to estimates by the Lupus Foundation of America (LFA), 1.5 Million Americans currently suffer from lupus, with 16,000 new cases reported annually. Tragically, lupus strikes mostly women of child-bearing age. Worldwide, the LFA estimates that at least five million people may have some form of the disease. Of the people diagnosed, approximately two-thirds will develop CLE. The annual average cost to provide medical treatment for a person with lupus: $6,000 to $10,000, with some treatment costing several thousand dollars a month.
"Management is extremely pleased to partner with Zylö Therapeutics, enhancing our portfolio of unique treatments for patients suffering from various dermatological related ailments," stated, Mr. Robb Knie, CEO of Hoth Therapeutics. "Zylö's initial work shows significant promise in combating Cutaneous Lupus Erythematosus, and we look forward to working with them in order to bring this treatment to market."
"We are thrilled to partner with Hoth, a company that is committed to innovative solutions and partnerships to develop treatments for diseases with a high unmet clinical need, such as lupus," said Scott Pancoast, CEO of Zylö. "As we work with the Hoth team to advance AEA-loaded Z-pods through the next stages of development, we expect to further demonstrate the important role that our patented Z-pod delivery system plays in improving treatment outcomes."
The term sheet is non-binding and neither party thereto shall have any obligation to consummate a transaction of any kind until such time as the parties have entered into a mutually agreeable definitive agreement. There can be no assurance that any such definitive agreement will be entered into or that the transaction will be completed on the terms set forth in the term sheet, or at all.
Market Outlook:
Atopic dermatitis market predicted to grow $7.2B in 2017 to $24B by end of 2027.
It affects more than 32 million patients in the US.
Diabetic Foot Ulcers affect approximately 9.1-26.1M people worldwide, about 19 34% of people with diabetes are likely to be affected.
Nearly 7.5 million people are affected by psoriasis in the US alone and represent about 2% of the population with approximately 100,000 new cases reported each year.*
60 million people suffering from all grades of acne in the US, 20% of which is severe enough to result in facial scarring.
Technical Analysis
As we stated above, with HOTH's tiny 3.2M float, any type of market friendly news could send its shares soaring.
HOTH suffered a sharp pullback today creating the perfect "Buy the Dip" opportunity.
HOTH has plenty of room to the upside, a move back to its 52-week high of $13.88 would net traders over +100% in profit from today's alert price.
We've done our very own chart analysis and see the potential for a move to $13.82.
HOTH has shown very little resistance once it breaks $8.80.
We see a strong uptrend, and an impulse to move higher.
This is a potential triple-digit gain opportunity
The Bottom-Line
We love these low-float bio-tech alerts.
They have the tendency to breakout faster and bigger than any other sector.
HOTH has the potential to be the next RWLK , and could lead the NASDAQ in gains tomorrow.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated twenty thousand dollars by Source 4 Communications LLC to conduct a two-day investor relations advertising and marketing campaign for HOTH. . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Add $ANFI to the top of your watchlist. SIgns $6M Contract +
=====================
ANFI ( Amira Nature Foods Ltd .)
Float: 25.82M
Alert Price: $1.05
Target Price: $6.00
Chart Analysis
Investor Presentation
Investor Webcast
Website | Recent News
========================
Members,
Our biggest NYSE-listed winner of 2019 looks ready to breakout big once again!
It's time to add ANFI ( Amira Nature Foods Ltd .) back to the top of your watchlist.
After pulling back substantially from its 52-week high, ANFI appears to have found its bottom.
The Company has recently made some market friendly announcements that we believe will serve as huge catalysts for an epic chart reversal.
Announced the hiring of Brian M. Speck as Chief Financial Officer. With his many years of U.S. public company accounting experience Mr. Speck will assist ANFI in Westernizing their finance department as they focus on the international growth of their brands.
Entered into contracts, which consist of approximately $9 million in revenue, to supply rice and institutional products to new customers in the Europe, Middle East, and Africa (“EMEA”) and Asia regions. The Company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020. “We are extremely pleased to announce this order, which along with our previously announced customer order of $42M, amounts to over $51M. This equates to securing 26% of our forecasted $200M of FY2020 revenue just 52 days (14%) into the fiscal year”, stated Karan A. Chanana, Amira’s Chairman.
ANFI's recent strategic moves have us extremely bullish on this past triple-digit winner.
In fact, we've done our very own chart analysis and see the potential for a move of over +153% in the very near future!
If you've been following our recent alerts, you should know that our price targets have been pretty much right on the money.
But that price target is quite modest compared to what Wall Street analysts are betting on.
Top 10 Wealth Firm Puts $6.00 Price Target on a $1.00 Stock
Jefferies analyst Akshay Jagdale recently maintained his Buy rating on ANFI and set a price target of $6.
That's an upside of +471% from today's alert price!
If you go to Google and search for the "Top 10 Wealth Firms" you'll notice that " Jefferies Wealth Management" is in the top 10 in the country.
If that wasn't enough to have you sold on ANFI , you'll be happy to know that Jefferies isn't the only equity research firm that is bullish on ANFI ...
Diamond Equity Research, a leading equity research and corporate access firm with a focus on small capitalization public companies recently initiated coverage on ANFI , and slapped on a $4.00 price target!
That's well over +280% in upside potential from today's alert price.
Their full research report is available here.
To say that ANFI is undervalued at its current share price would be the understatement of the year.
Here are a few other reasons why we have an extremely bullish outlook ANFI:
Low float of just 25.82M
Listed on the NYSE (High Liquidity)
Products now available on Amazon in the United Kingdom. The Company is initially offering its Brown Basmati Rice 2kg product and is looking forward to adding more products.
Reiterated its $200 million revenue guidance for the 2020 fiscal year ending March 31, 2020. Going forward, the Company’s focus will be on strengthening its international business and as such the 2020 fiscal year $200 million revenue guidance consists solely of international revenue (ex-India).
Jefferies analyst Akshay Jagdale recently maintained his Buy rating on ANFI and set a price target of $6.
Trading well below its average analyst price target of $6.00 (+471% Upside)
Its previously announced $30 million contract to supply third party branded basmati rice to a repeat customer in the Europe, Middle East, and Africa (“EMEA”) region was increased to $42 million within the provisions of the contract. The Company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020.
It's Indian subsidiary, Amira Foods India (“Amira India”), has converted Amira India debt into ordinary shares of Amira India. As a result of the debt conversion, the Company’s ownership in Amira India decreased from 80.4% to 49.8%. This event is a continuation of Amira’s focus on strengthening the Company’s international business.
It is our opinion that ANFI is shaping up to be one of the top growth/value plays listed on the NYSE at the moment.
As such, we ask that all members start their research on ANFI immediately, and consider building a position this morning at 9:30AM EST
About Amira Nature Foods
Founded in 1915, Amira has evolved into a global provider of packaged Indian specialty rice, with sales in over 40 countries today. Amira sells Basmati rice, premium long-grain rice grown only in certain regions of the Indian sub-continent, under their flagship Amira brand as well as under other third party brands. Amira sells its products primarily in emerging markets through a broad distribution network. Amira’s headquarters are in Dubai, United Arab Emirates, and it also has offices in India, Germany, the United Kingdom, and the United States.
Company Highlights:
Large Staple Consumer Category with Highly Supportive Industry and Sub Category Fundamentals
A Market Lead with Differentiated Business Model
Globally Diversified with Wide Customer Base and Broad Product Portfolio
Vertically Integrated "State-of-the-art" Supply Chain and Operations
Strong Financial Track Record, Underpinned by Stable Margins
Highly Experienced and Successful Management Team
Announced that its previously announced $30 million contract to supply third party branded basmati rice to a repeat customer in the Europe, Middle East, and Africa (“EMEA”) region was increased to $42 million within the provisions of the contract. The Company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020.
Since its founding in 1915, Amira has evolved from a domestic, family owned Indian business to a professionally managed, global branded, publicly traded, growing packaged food company.
Not only is the stock potentially undervalued based on its revenues and earnings , ANFI is also trading well below its book value, with a price-to-book ratio of 0.10, while the industry average is 1.81.
With ANFI trading well below the industry average for some key valuation ratios, it could be a value play, and could even attract potential buyers.
Moreover, Amira was able to increase at a compound annual growth rate of 15.5% between 2010 and 2017. With such high revenue growth rates, this company could be significantly undervalued by the market.
According to Finviz, over 50% of the company is owned by insiders. That in mind, that shows that the company’s officers, directors, and key insiders are confident in the company.
The Company has received numerous accolades:
Since 2010, Amira has been recognized in multiple years by the World Economic Forum as a “Global Growth Company”, an
invitation-only community consisting of ~300 of the world’s fastest-growing corporations
The World Consulting & Research Corporation named Amira one of “Asia’s Most Promising Brands”
Planman Marcom voted Amira the “INDIAN POWERBRAND” in the Food Category in 2011 and 2013
Amir was voted best partner in the “Staples” category in 2013 at the Bharti Walmart Private Limited Annual Supplier Conference
VWP World Brand recognized the Amira Brand as “The Admired Brand of India” in 2014–2015
Inc. India featured Amira as one of India’s fastest growing mid-sized companies in 2010, 2011, 2012 and 2013
Product Portfolio
Approximately three quarters of sales come from Basmati rice, the core focus of the company;
Sells more than 20 owned brands globally, spanning numerous price points;
Amira in India
Amira has established 15 Company managed distribution centers in India to provide it greater control over its expansion efforts in its home country location.
Amira is one of a handful of large relevant players in the domestic India market.
Amira represents a meaningful opportunity to consolidate the market over time.
Business Is Growing, Strategic Moves Will Expedite Growth
Amira Foods is no startup. The international business is healthy and generated roughly $270 million in sales in 2018. Those numbers are coupled with respectable margins that rested at 14.3% of gross sales. However, the company expects to do better with the expectation to add an additional 100bp to the international margins. Notably, there will some be shrinkage to the margins, which may be adjusted lower to account for the separation of the Indian business, due to less vertical integration and less sourcing from the primary processor. However, even with the expected reductions in the margin and certain efficiencies, analysts are pointing to ANFI being able to maintain separate sales of roughly $200 million, albeit with a lower margin of approximately 650bp. However, even with the expected short-term declines, the assumption of the lesser $200 million in sales coupled with an EBITDA margin of an expected 8.8%, can imply that ANFI will generate a positive EBITDA run of roughly $17 million. And, that is a healthy number to build upon.
Source: https://seekingalpha.com/instablog/49294...
Recent Developments
Appointment of Thomas Dennhardt (formerly Lidl) to CEO of Amira Basmati Rice GmbH (German subsidiary)
Board appointment of Hervé Larren (formerly LVMH), bringing experience in building brands internationally
EUR25mn Debt raise at 8.5% interest rate (due December 2023)
Reduced ownership of India subsidiary to 49.8%
Regains Compliance with NYSE Listing Requirements
Latest News
Amira Nature Foods Ltd Hires Brian M. Speck as Chief Financial Officer
Amira Nature Foods Ltd (the "Company") ( ANFI ), a global provider of packaged specialty rice, today announced the hiring of Brian M. Speck as Chief Financial Officer. The Company continues to focus on the international growth of its brands and as such, continues to take steps to Westernize its corporate finance and executive team.
Karan A. Chanana, Amira’s Chairman, commented, “Brian Speck is an excellent addition to our team, bringing his extensive financial and consumer industry background to the Company. We believe his many years of U.S. public company accounting experience will assist Amira in Westernizing our finance department as we focus on the international growth of our brands.”
“I am excited to join the Company at a pivotal time in its history and helping it realize its international growth strategy,” Mr. Speck said. “After spending nearly two decades in various accounting roles, I look forward to bringing my experience to assist Amira’s efforts to grow its brands outside of India.”
Since March 2018, Mr. Speck has been the Chief Financial Officer of Surge Holdings, Inc., a provider of a suite of financial and telecommunications services which are primarily marketed through small retail establishments which are utilized by members of its target market. Since October 2013, Mr. Speck has also been Director of Financial Reporting for Brio Financial Group, which the Company recently announced would be assisting the Company in its ongoing financial reporting. In his capacity at Brio, Mr. Speck consults various private and public companies in financial reporting, internal control development and evaluation, budgeting and forecasting. Prior to joining Brio, from 2011 to 2013, he was an audit supervisor at Wiss & Company. In that capacity, he was involved in the firm’s accounting and tax practice with industry focuses in manufacturing, wholesalers, construction contractors and professional service firms. Mr. Speck received a Master of Science in Accounting from Kean University.
Market Outlook:
Amira operates in the global packaged rice market and is a leading provider of Basmati rice, a long-grain aromatic rice with favorable health attributes that can be grown only in specific regions of the Indian sub-continent and part of the Punjab region located in Pakistan. The global rice market is an enormous market with stable growth, while specialty rice and specifically Basmati rice benefits from premium pricing and increasing consumption patterns. Demand for Basmati rice has remained strong over the past 10 years due to the increased consumption trends both in India and internationally. Leading players such as McCormick & Co., Hain Celestial, Rice 'n Spice, LT Foods , East End Foods , and Amira Nature Foods serve local as well as global consumers, which is reflected in the growth of Basmati rice market. The size of worldwide Basmati rice market was approximately $10.51 Billion in 2017 and is estimated to be worth $17.74 Billion by the end of 2022, with a robust CAGR of 11% between 2017 and 2022, according to Transparency Market Research (TMR).
Rice is a $275bn Global Staple Category with Favorable Market Conditions
Rice is the primary staple for >50% of the world’s population and provides > 20% of the global caloric intake
Represents 30% of caloric consumption in Asia(4)
Defensive and non-cyclical with steady growth
Improves with age and has an extremely long shelf life (up to 5+ years) if stored properly
Global rice consumption is growing, estimated to reach c.483 million metric tonnes in 2017(5)
The global rice market is estimated at $275B and has grown at 2% volume CAGR over the 2010 – 2015 period
Technical Analysis
As we stated above, we've done our very own chart analysis and see the potential for a move of over +153% from here!
We see a positive reversal from long-term support right here, and a positive cross looks imminent.
The float of ANFI is extremely low for a NYSE listed company at just 25.82M.
We know this ticker can make big moves on volume , so we wouldn't be too surprised if this ticker starts to breakout early.
With its bullish $6.00 price target, we believe its upside potential far outweighs any downside risk.
The Bottom Line
ANFI has proven its ability run-up big in both the short and long-term.
ANFI has the potential to be the biggest gainer on the NYSE, and deserves to be on the top of your watchlist.
That being said, we ask that all members start their research on ANFI immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources In LLC to conduct investor relations advertising and marketing for ANFI . We have previously been compensated ten thousand dollars by World Wide Holdings dba Invictus Resources In LLC to conduct investor relations advertising and marketing for ANFI on three separate occasions which have expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Add $ANFI to the top of your watchlist. SIgns $6M Contract +
=====================
ANFI ( Amira Nature Foods Ltd .)
Float: 25.82M
Alert Price: $1.05
Target Price: $6.00
Chart Analysis
Investor Presentation
Investor Webcast
Website | Recent News
========================
Members,
Our biggest NYSE-listed winner of 2019 looks ready to breakout big once again!
It's time to add ANFI ( Amira Nature Foods Ltd .) back to the top of your watchlist.
After pulling back substantially from its 52-week high, ANFI appears to have found its bottom.
The Company has recently made some market friendly announcements that we believe will serve as huge catalysts for an epic chart reversal.
Announced the hiring of Brian M. Speck as Chief Financial Officer. With his many years of U.S. public company accounting experience Mr. Speck will assist ANFI in Westernizing their finance department as they focus on the international growth of their brands.
Entered into contracts, which consist of approximately $9 million in revenue, to supply rice and institutional products to new customers in the Europe, Middle East, and Africa (“EMEA”) and Asia regions. The Company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020. “We are extremely pleased to announce this order, which along with our previously announced customer order of $42M, amounts to over $51M. This equates to securing 26% of our forecasted $200M of FY2020 revenue just 52 days (14%) into the fiscal year”, stated Karan A. Chanana, Amira’s Chairman.
ANFI's recent strategic moves have us extremely bullish on this past triple-digit winner.
In fact, we've done our very own chart analysis and see the potential for a move of over +153% in the very near future!
If you've been following our recent alerts, you should know that our price targets have been pretty much right on the money.
But that price target is quite modest compared to what Wall Street analysts are betting on.
Top 10 Wealth Firm Puts $6.00 Price Target on a $1.00 Stock
Jefferies analyst Akshay Jagdale recently maintained his Buy rating on ANFI and set a price target of $6.
That's an upside of +471% from today's alert price!
If you go to Google and search for the "Top 10 Wealth Firms" you'll notice that " Jefferies Wealth Management" is in the top 10 in the country.
If that wasn't enough to have you sold on ANFI , you'll be happy to know that Jefferies isn't the only equity research firm that is bullish on ANFI ...
Diamond Equity Research, a leading equity research and corporate access firm with a focus on small capitalization public companies recently initiated coverage on ANFI , and slapped on a $4.00 price target!
That's well over +280% in upside potential from today's alert price.
Their full research report is available here.
To say that ANFI is undervalued at its current share price would be the understatement of the year.
Here are a few other reasons why we have an extremely bullish outlook ANFI:
Low float of just 25.82M
Listed on the NYSE (High Liquidity)
Products now available on Amazon in the United Kingdom. The Company is initially offering its Brown Basmati Rice 2kg product and is looking forward to adding more products.
Reiterated its $200 million revenue guidance for the 2020 fiscal year ending March 31, 2020. Going forward, the Company’s focus will be on strengthening its international business and as such the 2020 fiscal year $200 million revenue guidance consists solely of international revenue (ex-India).
Jefferies analyst Akshay Jagdale recently maintained his Buy rating on ANFI and set a price target of $6.
Trading well below its average analyst price target of $6.00 (+471% Upside)
Its previously announced $30 million contract to supply third party branded basmati rice to a repeat customer in the Europe, Middle East, and Africa (“EMEA”) region was increased to $42 million within the provisions of the contract. The Company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020.
It's Indian subsidiary, Amira Foods India (“Amira India”), has converted Amira India debt into ordinary shares of Amira India. As a result of the debt conversion, the Company’s ownership in Amira India decreased from 80.4% to 49.8%. This event is a continuation of Amira’s focus on strengthening the Company’s international business.
It is our opinion that ANFI is shaping up to be one of the top growth/value plays listed on the NYSE at the moment.
As such, we ask that all members start their research on ANFI immediately, and consider building a position this morning at 9:30AM EST
About Amira Nature Foods
Founded in 1915, Amira has evolved into a global provider of packaged Indian specialty rice, with sales in over 40 countries today. Amira sells Basmati rice, premium long-grain rice grown only in certain regions of the Indian sub-continent, under their flagship Amira brand as well as under other third party brands. Amira sells its products primarily in emerging markets through a broad distribution network. Amira’s headquarters are in Dubai, United Arab Emirates, and it also has offices in India, Germany, the United Kingdom, and the United States.
Company Highlights:
Large Staple Consumer Category with Highly Supportive Industry and Sub Category Fundamentals
A Market Lead with Differentiated Business Model
Globally Diversified with Wide Customer Base and Broad Product Portfolio
Vertically Integrated "State-of-the-art" Supply Chain and Operations
Strong Financial Track Record, Underpinned by Stable Margins
Highly Experienced and Successful Management Team
Announced that its previously announced $30 million contract to supply third party branded basmati rice to a repeat customer in the Europe, Middle East, and Africa (“EMEA”) region was increased to $42 million within the provisions of the contract. The Company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020.
Since its founding in 1915, Amira has evolved from a domestic, family owned Indian business to a professionally managed, global branded, publicly traded, growing packaged food company.
Not only is the stock potentially undervalued based on its revenues and earnings , ANFI is also trading well below its book value, with a price-to-book ratio of 0.10, while the industry average is 1.81.
With ANFI trading well below the industry average for some key valuation ratios, it could be a value play, and could even attract potential buyers.
Moreover, Amira was able to increase at a compound annual growth rate of 15.5% between 2010 and 2017. With such high revenue growth rates, this company could be significantly undervalued by the market.
According to Finviz, over 50% of the company is owned by insiders. That in mind, that shows that the company’s officers, directors, and key insiders are confident in the company.
The Company has received numerous accolades:
Since 2010, Amira has been recognized in multiple years by the World Economic Forum as a “Global Growth Company”, an
invitation-only community consisting of ~300 of the world’s fastest-growing corporations
The World Consulting & Research Corporation named Amira one of “Asia’s Most Promising Brands”
Planman Marcom voted Amira the “INDIAN POWERBRAND” in the Food Category in 2011 and 2013
Amir was voted best partner in the “Staples” category in 2013 at the Bharti Walmart Private Limited Annual Supplier Conference
VWP World Brand recognized the Amira Brand as “The Admired Brand of India” in 2014–2015
Inc. India featured Amira as one of India’s fastest growing mid-sized companies in 2010, 2011, 2012 and 2013
Product Portfolio
Approximately three quarters of sales come from Basmati rice, the core focus of the company;
Sells more than 20 owned brands globally, spanning numerous price points;
Amira in India
Amira has established 15 Company managed distribution centers in India to provide it greater control over its expansion efforts in its home country location.
Amira is one of a handful of large relevant players in the domestic India market.
Amira represents a meaningful opportunity to consolidate the market over time.
Business Is Growing, Strategic Moves Will Expedite Growth
Amira Foods is no startup. The international business is healthy and generated roughly $270 million in sales in 2018. Those numbers are coupled with respectable margins that rested at 14.3% of gross sales. However, the company expects to do better with the expectation to add an additional 100bp to the international margins. Notably, there will some be shrinkage to the margins, which may be adjusted lower to account for the separation of the Indian business, due to less vertical integration and less sourcing from the primary processor. However, even with the expected reductions in the margin and certain efficiencies, analysts are pointing to ANFI being able to maintain separate sales of roughly $200 million, albeit with a lower margin of approximately 650bp. However, even with the expected short-term declines, the assumption of the lesser $200 million in sales coupled with an EBITDA margin of an expected 8.8%, can imply that ANFI will generate a positive EBITDA run of roughly $17 million. And, that is a healthy number to build upon.
Source: https://seekingalpha.com/instablog/49294...
Recent Developments
Appointment of Thomas Dennhardt (formerly Lidl) to CEO of Amira Basmati Rice GmbH (German subsidiary)
Board appointment of Hervé Larren (formerly LVMH), bringing experience in building brands internationally
EUR25mn Debt raise at 8.5% interest rate (due December 2023)
Reduced ownership of India subsidiary to 49.8%
Regains Compliance with NYSE Listing Requirements
Latest News
Amira Nature Foods Ltd Hires Brian M. Speck as Chief Financial Officer
Amira Nature Foods Ltd (the "Company") ( ANFI ), a global provider of packaged specialty rice, today announced the hiring of Brian M. Speck as Chief Financial Officer. The Company continues to focus on the international growth of its brands and as such, continues to take steps to Westernize its corporate finance and executive team.
Karan A. Chanana, Amira’s Chairman, commented, “Brian Speck is an excellent addition to our team, bringing his extensive financial and consumer industry background to the Company. We believe his many years of U.S. public company accounting experience will assist Amira in Westernizing our finance department as we focus on the international growth of our brands.”
“I am excited to join the Company at a pivotal time in its history and helping it realize its international growth strategy,” Mr. Speck said. “After spending nearly two decades in various accounting roles, I look forward to bringing my experience to assist Amira’s efforts to grow its brands outside of India.”
Since March 2018, Mr. Speck has been the Chief Financial Officer of Surge Holdings, Inc., a provider of a suite of financial and telecommunications services which are primarily marketed through small retail establishments which are utilized by members of its target market. Since October 2013, Mr. Speck has also been Director of Financial Reporting for Brio Financial Group, which the Company recently announced would be assisting the Company in its ongoing financial reporting. In his capacity at Brio, Mr. Speck consults various private and public companies in financial reporting, internal control development and evaluation, budgeting and forecasting. Prior to joining Brio, from 2011 to 2013, he was an audit supervisor at Wiss & Company. In that capacity, he was involved in the firm’s accounting and tax practice with industry focuses in manufacturing, wholesalers, construction contractors and professional service firms. Mr. Speck received a Master of Science in Accounting from Kean University.
Market Outlook:
Amira operates in the global packaged rice market and is a leading provider of Basmati rice, a long-grain aromatic rice with favorable health attributes that can be grown only in specific regions of the Indian sub-continent and part of the Punjab region located in Pakistan. The global rice market is an enormous market with stable growth, while specialty rice and specifically Basmati rice benefits from premium pricing and increasing consumption patterns. Demand for Basmati rice has remained strong over the past 10 years due to the increased consumption trends both in India and internationally. Leading players such as McCormick & Co., Hain Celestial, Rice 'n Spice, LT Foods , East End Foods , and Amira Nature Foods serve local as well as global consumers, which is reflected in the growth of Basmati rice market. The size of worldwide Basmati rice market was approximately $10.51 Billion in 2017 and is estimated to be worth $17.74 Billion by the end of 2022, with a robust CAGR of 11% between 2017 and 2022, according to Transparency Market Research (TMR).
Rice is a $275bn Global Staple Category with Favorable Market Conditions
Rice is the primary staple for >50% of the world’s population and provides > 20% of the global caloric intake
Represents 30% of caloric consumption in Asia(4)
Defensive and non-cyclical with steady growth
Improves with age and has an extremely long shelf life (up to 5+ years) if stored properly
Global rice consumption is growing, estimated to reach c.483 million metric tonnes in 2017(5)
The global rice market is estimated at $275B and has grown at 2% volume CAGR over the 2010 – 2015 period
Technical Analysis
As we stated above, we've done our very own chart analysis and see the potential for a move of over +153% from here!
We see a positive reversal from long-term support right here, and a positive cross looks imminent.
The float of ANFI is extremely low for a NYSE listed company at just 25.82M.
We know this ticker can make big moves on volume , so we wouldn't be too surprised if this ticker starts to breakout early.
With its bullish $6.00 price target, we believe its upside potential far outweighs any downside risk.
The Bottom Line
ANFI has proven its ability run-up big in both the short and long-term.
ANFI has the potential to be the biggest gainer on the NYSE, and deserves to be on the top of your watchlist.
That being said, we ask that all members start their research on ANFI immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources In LLC to conduct investor relations advertising and marketing for ANFI . We have previously been compensated ten thousand dollars by World Wide Holdings dba Invictus Resources In LLC to conduct investor relations advertising and marketing for ANFI on three separate occasions which have expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
$BTC NO NEED TO SWITCH TO BEARISH VIEW YET
Some were surprised by yesterday's price action but we all need to remember that this is Crypto and manipulation and whale activity can result in huge spikes on a minute to minute basis. The critical support level held and
maintained the bullish structure of the chart, we hope for a positive move towards the $9600 area to complete the 5th wave before a much more severe correction. We will be taking profits and waiting to buy on the next dip if that scenario plays out. The alternative is that we break bearishly from the new channel and through the $7700 support with $6600 asa downside reversal target. Any such breakdown longs will be laddered in from the $7000 area depending on velocity of decline. Be safe trading and protect profits $7700 is the KEY SUPPORT
$BTC NO NEED TO SWITCH TO BEARISH VIEW YET
Some were surprised by yesterday's price action but we all need to remember that this is Crypto and manipulation and whale activity can result in huge spikes on a minute to minute basis. The critical support level held and
maintained the bullish structure of the chart, we hope for a positive move towards the $9600 area to complete the 5th wave before a much more severe correction. We will be taking profits and waiting to buy on the next dip if that scenario plays out. The alternative is that we break bearishly from the new channel and through the $7700 support with $6600 asa downside reversal target. Any such breakdown longs will be laddered in from the $7000 area depending on velocity of decline. Be safe trading and protect profits $7700 is the KEY SUPPORT
$BTC NO NEED TO SWITCH TO BEARISH VIEW YET
Some were surprised by yesterday's price action but we all need to remember that this is Crypto and manipulation and whale activity can result in huge spikes on a minute to minute basis. The critical support level held and
maintained the bullish structure of the chart, we hope for a positive move towards the $9600 area to complete the 5th wave before a much more severe correction. We will be taking profits and waiting to buy on the next dip if that scenario plays out. The alternative is that we break bearishly from the new channel and through the $7700 support with $6600 asa downside reversal target. Any such breakdown longs will be laddered in from the $7000 area depending on velocity of decline. Be safe trading and protect profits $7700 is the KEY SUPPORT
$CRM EARNINGS BETTER BE A BLOWOUT TO AVOID MORE DOWNSIDE.
Once the piggy bank stock where you investment was safe has turned a little weaker in recent weeks. The tech massacre has affected the high valuation names in particular and NYSE:CRM certainly fits into that category with a high p/e ratio of 100. The chart is getting increasing weak with indicators all bearish , as is the volume , with high volume on down days which is extremely bearish . On the downside $134 seems like a possible target BUT 3 TREND LINES BELOW COULD GIVE SUPPORT.
AVERAGE ANALYSTS PRICE TARGET $182
AVERAGE ANALYSTS RECOMMENDATION BUY
$CRM EARNINGS BETTER BE A BLOWOUT TO AVOID MORE DOWNSIDE.
Once the piggy bank stock where you investment was safe has turned a little weaker in recent weeks. The tech massacre has affected the high valuation names in particular and NYSE:CRM certainly fits into that category with a high p/e ratio of 100. The chart is getting increasing weak with indicators all bearish , as is the volume , with high volume on down days which is extremely bearish . On the downside $134 seems like a possible target BUT 3 TREND LINES BELOW COULD GIVE SUPPORT.
AVERAGE ANALYSTS PRICE TARGET $182
AVERAGE ANALYSTS RECOMMENDATION BUY
$AEO RISKY REVERSAL TRADE INTO EARNINGS
The current mixed bag of results in the retail sector makes this a difficult call coming into earnings and high volatility is expected post earnings . We are biased on the bull case but on our chart we have included a bearish view, where we still have to complete the C wave in correction. Regardless of the outcome there is profits to be had, as the upside and downside have quite a lot of room to run.
AVERAGE ANALYSTS PRICE TARGET $24.57
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
SHORT INTEREST 10%
$AEO RISKY REVERSAL TRADE INTO EARNINGS
The current mixed bag of results in the retail sector makes this a difficult call coming into earnings and high volatility is expected post earnings . We are biased on the bull case but on our chart we have included a bearish view, where we still have to complete the C wave in correction. Regardless of the outcome there is profits to be had, as the upside and downside have quite a lot of room to run.
AVERAGE ANALYSTS PRICE TARGET $24.57
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
SHORT INTEREST 10%
$SLS TOP WATCHLIST STOCK, ON TUMOR DATA
POSITIVE DATA RELEASED ON PHASE SELLAS AnnounceS Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S. KEEP ON WATCH FOR SOME VERY POSITIVE MOVES.
SHORT INTEREST 13.2%
AVERAGE ANALYSTS PRICE TARGET $8.75
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
$SLS TOP WATCHLIST STOCK, ON TUMOR DATA
POSITIVE DATA RELEASED ON PHASE SELLAS AnnounceS Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S. KEEP ON WATCH FOR SOME VERY POSITIVE MOVES.
SHORT INTEREST 13.2%
AVERAGE ANALYSTS PRICE TARGET $8.75
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
$AMBA Earnings should be ok, but China is the problem.
On the 22nd may shares of NASDAQ:AMBA fell 12% following reports that its chinese customer HIK would be added to the banned list. Possibly a knee jerk reaction as this is purely speculation and AMBA is not actually registered in the USA. The earnings call might shed some light on the issue. On a more positive issue AMBA recently announced a exciting partnership with Baolong Technology to develop a advanced AI driver monitoring platform. Buyers have returned to the name in the last few days running into earnings which is encouraging and AMBA is expected to meet or beat expectations. This is a risky sector to be getting into in the current market but has a high RR and the short interest could help propel the stock on any rally.
$AMBA Earnings should be ok, but China is the problem.
On the 22nd may shares of NASDAQ:AMBA fell 12% following reports that its chinese customer HIK would be added to the banned list. Possibly a knee jerk reaction as this is purely speculation and AMBA is not actually registered in the USA. The earnings call might shed some light on the issue. On a more positive issue AMBA recently announced a exciting partnership with Baolong Technology to develop a advanced AI driver monitoring platform. Buyers have returned to the name in the last few days running into earnings which is encouraging and AMBA is expected to meet or beat expectations. This is a risky sector to be getting into in the current market but has a high RR and the short interest could help propel the stock on any rally.
$FB HOLDING ITS TECHNICALS AMID MASSACRE
WHAT A DISASTER OF A MONDAY FOR TECH AND THE COMMUNICATIONS SECTOR IN PARTICULAR, SPECULATION REGARDING DEPT OF JUSTICE INVESTIGATIONS INTO GOOGLE HAS SENT THE SECTOR INTO A TAILSPIN. DESPITE THIS FB HAS FOUND SOME SUPPORT ON KEY TECHNICAL LEVELS. THIS SUPPORT BETTER HOLD AS THERE IS A WORLD OF HURT BELOW. POSSIBLE LONG ENTRY TUESDAY/WEDNESDAY.
$FB HOLDING ITS TECHNICALS AMID MASSACRE
WHAT A DISASTER OF A MONDAY FOR TECH AND THE COMMUNICATIONS SECTOR IN PARTICULAR, SPECULATION REGARDING DEPT OF JUSTICE INVESTIGATIONS INTO GOOGLE HAS SENT THE SECTOR INTO A TAILSPIN. DESPITE THIS FB HAS FOUND SOME SUPPORT ON KEY TECHNICAL LEVELS. THIS SUPPORT BETTER HOLD AS THERE IS A WORLD OF HURT BELOW. POSSIBLE LONG ENTRY TUESDAY/WEDNESDAY.